API | cd19 car-t cells

cd19 car-t cells Report issue

Cell therapy Experimental

AACT

Active Ingredient History

NOW

Now

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanisms of Action: Missing data
Multi-specific: Missing data
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

acd19z cells | anti-cd19 car t cells | anti-cd19 car-t cells | anti-cd19-car t cells | anti-cd19-car-t cells | autologous anti-cd19 car t cells | autologous cd19-targeting car t cells | car19 t-cells | car-cd19 | car-cd19 t cells | cart-19 | cart-19 autologous t-cells | car-t cd19 | cart cd19 cells | cart cd19 t cells | cd19 car gene transduced t lymphocytes | cd19 car t cells | cd19 car-t cells | cd19-car-t cells | cd19cat-41bbz car t-cells | cd19 gene-modified t cells targeted | cd19-specific t cell infusion | hucart19 | im19 car-t | rna anti-cd19 car t cells | t cells genetically targeted to the b cell specific antigen cd19 | ucart019 | ucart19

Organizations (135)

Research & Development (135)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (37)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (37)

Acute Febrile Encephalopathy (Phase 1)

Antigens, CD19 (Phase 2)

Arthritis, Rheumatoid (Phase 1)

Automobiles (Phase 1)

Blood Transfusion (Phase 2)

Bone Marrow Transplantation (Phase 2)

Burkitt Lymphoma (Phase 3)

Drugs, Investigational (Phase 2)

Electroconvulsive Therapy (Phase 1)

Endoscopy (Phase 1)

Hematologic Neoplasms (Phase 1)

Hodgkin Disease (Phase 2)

Leukemia (Phase 1/Phase 2)

Leukemia, B-Cell (Phase 3)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 3)

Leukemia, Lymphoid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2/Phase 3)

Leukemia, Prolymphocytic (Phase 1)

Leukemia, Prolymphocytic, B-Cell (Phase 1/Phase 2)

Lupus Erythematosus, Systemic (Phase 1)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 3)

Lymphoma, Follicular (Phase 3)

Lymphoma, Large B-Cell, Diffuse (Phase 3)

Lymphoma, Large-Cell, Immunoblastic (Phase 3)

Lymphoma, Mantle-Cell (Phase 3)

Lymphoma, Non-Hodgkin (Phase 2)

Multiple Myeloma (Phase 2)

Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 1)

Pediatrics (Phase 2)

Pharmacological and Toxicological Phenomena (Phase 2)

POEMS Syndrome (Phase 1)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2/Phase 3)

Recurrence (Phase 1/Phase 2)

Risk Factors (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 214
# of Trial Organizations: 135

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue